MPM BioImpact’s Viracta Therapeutics VIRX Stock Holding History
Bought
Maintained
Sold
Other funds holding VIRX
BBA
MPM BioImpact's VIRX Position: Q2 2020 in Review
MPM BioImpact sold out of Viracta Therapeutics (VIRX) in Q2 2020, closing a stake of 80,283 shares — an estimated $1.17M sold.
MPM BioImpact first reported a position in VIRX in Q4 2019 and held it in 2 quarters. The position peaked at $1.17M in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.
- MPM BioImpact reported no remaining Viracta Therapeutics position as of Q2 2020 after selling out during the quarter.
- MPM BioImpact sold 80,283 Viracta Therapeutics shares in Q2 2020, an estimated $1.17M.
- MPM BioImpact first reported a position in Viracta Therapeutics in Q4 2019 and held it in 2 quarters.
- MPM BioImpact's Viracta Therapeutics position peaked at $1.17M in Q1 2020.
- 41 funds tracked by Wall St. Rank held Viracta Therapeutics as of Q2 2020.
Based on MPM BioImpact's 13F filing for Q2 2020, filed 12 Aug 2020.